Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1182397 | 0.90 | HRH3 (0.56) | PIK3CAPIK3CBADORA2AADORA1HRH3 | |
| SCHEMBL190250 | 0.88 | PIK3CA (0.50) | PIK3CAPIK3CBADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL190119 | 0.88 | PIK3CA (0.66) | PIK3CAPIK3CBADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL1181730 | 0.86 | PIK3CA (0.53) | PIK3CAPIK3CBADORA2AADORA1HRH3 | |
| SCHEMBL1181231 | 0.86 | PIK3CA (0.50) | PIK3CAPIK3CBADORA2AADORA1HRH3 | |
| SCHEMBL14898422 | 0.85 | PIK3CA (0.50) | PIK3CAPIK3CBADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL993554 | 0.85 | PIK3CA (0.50) | PIK3CAPIK3CBADORA2AADORA1HRH3 | |
| SCHEMBL190321 | 0.85 | PIK3CA (0.64) | PIK3CAPIK3CB | |
| SCHEMBL4437399 | 0.85 | PIK3CA (0.55) | PIK3CAPIK3CBADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL189959 | 0.84 | PIK3CA (0.68) | PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885PIK3CB 6/4885ADORA2A 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.